The multiple biological activities present in semipurified lymphokine preparations have made it difficult to assign discrete biological functions to each lymphokine. As a result, the large number of identified lymphokine activities may actually reflect the manifestations of a few factors. While this research has also been hampered by the limited quantities of lymphokines available, hybridoma and recombinant DNA technologies have begun to help overcome these limitations.
The multiple biological activities present in semipurified lymphokine preparations have made it difficult to assign discrete biological functions to each lymphokine. As a result, the large number of identified lymphokine activities may actually reflect the manifestations of a few factors. While this research has also been hampered by the limited quantities of lymphokines available, hybridoma and recombinant DNA technologies have begun to help overcome these limitations.
Macrophage activation has been intensively investigated because it is generally agreed that activated macrophages play an essential role in the defense against microorganisms and in the immune response against neoplasia (1) . Macrophage activation mediated by macrophage activation factor (MAF) 1 and gamma interferon (IFN-'y) has been characterized by similar morphologic, metabolic, and functional changes (2-6) including stimulation of nonspecific tumoricidal activities (5), induction of Ia antigen expression (7, 8) , increased Fc receptor expression (0, 10), production of plasminogen activator (I 1), and production of hydrogen peroxide (12) . Several investigators (5, 8, 12, 13) have postulated therefore that IFN-q~ and MAF may be identical. In support, Schreiber et al. (14) have recently demonstrated biosynthetic and biochemical similarities of IFN-'y and MAF produced by a murine T cell hybridoma (24/G1). Both the antiviral and MAF activities of 24/G1 cultured supernatants were neutralized by anti-IFN-% but not anti-IFN-a and antMFN-B (15) . Although previous investigations (15) (16) (17) have demonstrated neutralization of MAF activity with polyclonal antMFN-7, definitive results could not be ascertained since these antisera were prepared from partially purified preparations and could contain antibodies that neutralize other lymphokine activities.
In the present report, murine IFN-~ produced by recombinant DNA techniques (18) (>00% pure) was tested for MAF activity; special attention was given Rabbit Antimurine IFN-y. The material used to immunize rabbits was recombinant murine IFN-7, expressed in E. coli (18) , of the same purity as previously described. The immunization schedule was as follows: On day 0, 200 #g protein (0.5 ml in complete Freund's adjuvant) was administered subcutaneously in six different sites. On day 10, 200 #g protein (in incomplete Freund's adjuvant) was administered intramuscularly. On day 20, 200 #g protein was administered intravenously. On day 24, the rabbit was bled.
Affinity Purification of Rabbit Antimurine IFN-~,. 12 mg of highly purified murine IFN-~, was coupled to ~2 ml affi-gel 10 resin (Bio°Rad Laboratories, Richmond, CA) as previously described (28) . Coupling efficiency was determined to be 81%, based on the protein mass recovered after washing of the resin. 2 ml of hyperimmune rabbit antimurine IFN-~, antiserum was dialyzed vs. phosphate-buffered saline (PBS), pH 7.4, and then applied to the murine IFN-~,/affi-gel 10 resin, which had previously been equilibrated vs. the same buffer in a 1 × 10 cm econocolumn (Bio-Rad Laboratories). 97% of the total protein applied was recovered in 10-bed volumes of PBS; antibodies (3% total protein) specifically bound to the IFN were eluted in 2-bed volumes 0.1 M sodium citrate, pH 3.0. Eluate was immediately adjusted to pH 7.8 with one-half volume 1 M Tris, pH 8.5. By enzyme-linked immunoabsorbent assay (ELISA) analysis (29) , all of the murine IFN-~,-binding capacity of the original hyperimmune antiserum sample was recovered in the specifically eluted pool; no binding activity was seen in the material that did not bind to the murine IFN-'~,/affi-gel 10.
Neutralization of MAF Activity. The IFN-7-neutralizing titer of rabbit antirecombinant murine IFN-7 serum was 200,000 U/ml. Neutralization of MAF activity was performed by the addition of 15 #1 antiserum to 2 ml of MAF-containing samples. For neutralization of human IFN-a ADbgl, murine IFN-a, and IFN-/3, 120 #1 of antiserum was used. After incubation at 37°C for 2 h, the samples were placed directly in the MAF and antiviral assays.
Stimulation for MAF Production. The medium used to stimulate cells for MAF production was Eagle's minimum essential medium (MEM) supplemented with 1 mM sodium pyruvate, 0.1 mM nonessential amino acids, 2 mM L-glutamine, twofold vitamin solution, 100 U/ml penicillin, 100 #g]ml streptomycin (Gibco Laboratories, Grand Island, NY) and 10% heat-inactivated fetal bovine sera (Sterile Systems, Inc., Logan, UT) (CMEM). Murine spleen cells were first purified by Ficoll°Paque (Pharmacia Fine Chemicals, Piscataway, N J) gradients. The monocytes were ctfltured in 10 ml of CMEM (5 × 106/ ml) in 15-ml plastic centrifuge tubes (Corning Glass Works, Corning, NY). After 48 h incubation at 37 °C in the presence of 5 #g/ml concanavalin A (Con A) (Sigma Chemical Co., St. Louis, MO), all supernatants were sterilized by passage through a 0.22 tzM filter (Millex-GS; Millipore Corp., Bedford, MA) and used immediately. Control supernatants were obtained from cells incubated without mitogen but reconstituted to the initial concentration of mitogen in the stimulated cultures after incubation.
RPMI 1788, EL4-17-2, hybridoma clone 3-57, or the murine cytotoxic T cell clones were seeded with 1.5 × t06 cells into 25-cm 2 plastic tissue culture flasks (Corning Glass Works). They were cultured as described above except that, in addition to Con A, 10 ng/ ml PMA (Sigma Chemical Co.), which is known to enhance IFN-7 production (30), was included.
Human platelet residues (American Red Cross, Needham, MA), bovine and ovine spleens (Armour and Company, Dixon, CA), and guinea pig spleen cells were purified by Ficoll-Paque and stimulated with Con A as described above.
Labeling of Tumor Cells. T-75-cm 2 tissue culture flasks (Corning Glass Works) contain- Macrophage Activation Assay. The macrophage activation assay was similar to that described by Fidler et ai. (34) with some modifications. Peritoneal exudate cells (PEC) were obtained from mice that were injected intraperitoneaily 5 d previously with 1.5 ml thioglycollate (Difco Laboratories, Detroit, MI). The PEC were harvested by injection of 10 ml cold Ca ++-and Mg++-free Hank's balanced salt solution (HBSS) (Gibco Laboratories), washed twice, and adjusted to 1 x 106 cells/ml in warm MEM. 200 #1 were distributed in each well of a 96-well flat-bottomed microtiter plate (Corning Glass Works). After incubation in a humidified atmosphere (37°C, 5% CO2) for 1 h, the plates were washed with warm MEM and aspirated to remove residual nonadherent cells. 200 #1 of the samples to be tested for MAF activity were added in replicates of six in the presence of 5 ng/ml lipopolysaccharide (LPS). Significant MAF activity in this assay requires 18 h exposure of PEC to activating agents. Hence, the PEC monolayers were activated for 24 h and washed in warm MEM before use. At this time, 1 X 104 [l~sI]IUdR-B16Fa0 tumor cells in 200 #1 were distributed to each well (effector cell/target cell ratio, 20:1). After 24-48 h of macrophage-tumor cell contact, 100 ~1 of the supernatant was collected and counted for isotope release in an automatic gamma counter (model 28150; Micromedic Systems, Huntsville, AL). Each assay contained tumor cells alone to determine background cytotoxicity (usually 0-5%). In addition, all plates contained 5 ~g/ml LPS (Sigma Chemical Co.) in CMEM as a positive control. All experiments were repeated at least three times and statistics were performed by the Student's t test. Results are presented as the percent specific tumor cytotoxicity (+ SEM) which was determined by: [(total test supernatant cpm -total control supernatant cpm)/(total cpm plated -total control supernatant cpm)] x 100. The SEM of six replicates did not exceed 5%.
Results
Length of Exposure Requirement. To determine the exposure time period required for 'conventional MAF' to stimulate PEC to express MAF activity, PEC was treated with Con A-conditioned media for several time periods (Table I ). Significant MAF activity was observed only when Con A-conditioned media (which contained 300 U/ml IFN-~') was exposed to PEC for 18 h; MAF activity was increased by exposure to PEC for 24 h. No significant MAF activity was Supernatants derived from murine spleen cells cultured for 48 h in the presence of 5 ~tg/ml Con A (Con A-conditioned media) or cultured cell supernatants adjusted to 5 #g/ml Con A at the end of culture (Con A control), and 5/zg/ml LPS were used to treat murine PEC for the time period indicated. PEC were then washed and incubated with [Ia*5]IUdRlabeled B16F10 tumor cells for 24 h. Results, determined by the amount of label released, represent the mean percent cytotoxicity of six replicates.
observed by treatment with the Con A-conditioned media control (which contained <6 U/ml IFN-3,). As a positive assay control, treatments of 5 ug/ml LPS were used and demonstrated similar exposure requirements for expression of MAF activity. Macrophage Activation by IFN-~. Greater than 99% pure recombinant murine IFN-~,, expressed in E. coli (18), from 0.1 to 100 U/ml was used to stimulate MAF activity in PEC (Fig. 1) . Significant levels of MAF activity were observed after 24 h of PEC-tumor cell contact in the presence of 100 U/ml, 25 U/ml, or 10 U/ml of IFN-~, (P < 0.05). When low levels of LPS (5 ng/ml) were included, significant MAF activity was detected with as little as 1 U/ml IFN-~,. PEC treated with only 5 ng/ml LPS showed only background levels of cytotoxicity, 0% in this experiment. The positive controls (PEC treated with 5 t~g/ml LPS) demonstrated 23% cytotoxicity.
Since the IFN-'~ used for investigation was derived from E. coli and since LPS is known to stimulate macrophages, various concentrations of LPS were tested for MAF activity (Fig. 2) . Significant levels of MAF activity were detected with LPS treatments, but only when concentrations exceeded 400 ng/ml. This agrees with previous reports (35, 36), where 500 ng/ml LPS was required to induce significant tumor cytotoxicity.
Kinetics of Macrophage Activation. A kinetic study was performed using treat- ments of 25 U/ml and 100 U/ml recombinant murine IFN-~, and 5 #g/ml LPS (Fig. 3) . Conventional MAF containing supernatants from C57BL/6 spleen cells treated with 5 #g/ml Con A for 48 h were included with their controls (spleen cells cultured without Con A but reconstituted to the initial concentration of Con A). Significant levels of MAF activity were first detected after 24 h of PECtumor interaction. PEC treated with 100 U/ml IFN-"r displayed 14.9 + 0.9% cytotoxicity (P < 0.001) and 5 #g/ml LPS displayed 8.6 + 1.5% cytotoxicity (P < 0.010). Highest levels of MAF activity were observed at 72 h. PEC treated with IFN-3' at 100 U/ml, 25 U/ml, 5 #g/ml LPS, or the Con A-stimulated spleen cell supernatant all displayed significant levels of MAF activity. IFN-3, treatments of 100 U/ml displayed the highest percentage of cytotoxicity (60.8 __. 4.8%). The Con A-stimulated spleen cell supernatant displayed 28.5 + 1.9% cytotoxicity while its control was not significant. The background cytotoxicity of PEC treated with media alone was only 4% (not significant).
Neutralization of Macrophage Activation. The IFN-~, titer of the Con A-treated spleen cell supernatant tested was 60 U/ml (Fig. 3) . The level of cytotoxicity observed for this supernatant was between the levels of cytotoxicity after treatment of PEC with 25 and 100 U/ml of IFN-% Since the amount of cytotoxicity in the Con A-treated spleen cell supernatant could be explained solely by the presence of IFN-3,, neutralization experiments were performed to determine whether MAF activity could be detected in the absence of IFN-~, antiviral activity. Murine spleen cells were incubated with Con A (as described in Materials and Methods) to generate MAF-containing supernatants and were used immediately upon collection. Supernatants were diluted 1:4 to 1:256 and divided into two portions. One portion was treated with rabbit anti-IFN-3'. After appropriate incubation, all samples were tested in the MAF and IFN-3, assay. The results of the antiviral assay (not shown) confirmed antiviral activity in the amount of 90 U/ml IFN-3, in the Con A-treated spleen cell supernatant (1:4 dilution). The same supernatant treated with anti-IFN-3' displayed <4 U/ml. Similarly, each dilution of the supernatant tested with the antibody-treated counterpart was in agreement, suggesting that the antiviral activity of IFN-3, was neutralized. High levels of MAF activity were found with all dilutions of the Con A-treated spleen cell supernatants (Fig. 4) . The highest dilution used (1:256), which represents 1.4 U/ml IFN-3,, gave significant levels of MAF activity (17.3 + 2.4%, P < 0.001). When Con A-treated spleen cell supernatants were treated with anti-IFN-% no significant MAF activity remained compared with the antibody control. PEC treated with 5 #g/ml LPS (positive assay control) demonstrated significant levels of MAF activity (36.0 ± 4.1%, P < 0.001). Antimurine IFN-~, had no effect on LPS stimulation of MAF activity. The antimurine IFN-y antibodies used in these neutralization experiments were generated in rabbits immunized with purified recombinant murine IFN-3,. A possibility that neutralization of MAF activity was due to the presence of antibody specificities against non-IFN-3, molecules was considered. Therefore, the polyclonal antibodies were purified by affinity chromatography. Complete neutralization of MAF activity found in Con A-stimulated murine spleen cell supernatants was observed when the polyclonal or affinity-purified antirecombinant murine IFN-y antibodies were used. No neutralization of MAF activity occurred when the unbound antibodies (flow through from affinity chromatography purification) was used. This indicated that neutralization of MAF activity was specific for the antirecombinant murine IFN-7 antibodies.
Macrophage Activation by Supernatants of Murine T Lymphocyte Lines. Three of four cloned murine interleukin 2-dependent cytotoxic T lymphocyte lines that were tested for MAF production are displayed in Fig. 5 . All three cell lines (CTLL-R9, CTLL-R 11, and CTLL-R 12) produced MAF activity constitutively, and MAF activity was increased when the cells were stimulated with Con A and PMA. Supernatants from CTLL-R9 displayed the highest level of MAF (and IFN-3,) activity. CTLL-R8 did not demonstrate MAF (or IFN-'r) production, even after stimulation (data not shown). While all of the cell lines are able to produce IFN-7 (37), no antiviral activity (<4 U/ml) was detected in unstimulated cell line supernatants that displayed MAF activity. This suggested that low levels of IFN-3,, below the sensitivity of the antiviral assay, were produced. When supernatants obtained from stimulated or unstimulated cell lines were treated with anti-IFN-'r, complete abrogation of MAF activity resulted. Discussion Many reagents such as LPS (16, 20) , muramyl dipeptide (38), PMA (39) , and ionophores (39-41) have been found to activate macrophages. The possibility of iymphokines participating in macrophage activation was first reported some 13 years ago when it was demonstrated that macrophages obtained from mice undergoing tumor rejection had tumoricidal capabilities (42) . Using purified recombinant IFN-7 and affinity-purified antibodies, we have demonstrated that murine IFN-'r has potent macrophage activation activity in the cytotoxicity assay employed. The possibility that macrophage activation was due to contaminating LPS in IFN-3, preparations can be excluded since these preparations contained <0.1 ng/ml LPS. Furthermore, the level of LPS required for MAF activity in this assay is 1,000-fold greater.
In support of these findings, recombinant murine IFN-3, obtained from cultured supernatants of COS-7 monkey kidney cells has recently been shown to display MAF activity (16, 43) . Although IFN-3, from the COS-7 cells was not purified, the possibility of macrophage activation by contaminating lymphokines and LPS can be excluded.
Nathan et al. (12) have recently demonstrated human monocyte activation after treatment with purified recombinant human IFN-3, expressed in E. coli (Genentech, Inc.). Significant enhancement of hydrogen peroxide secretion and induction of toxoplasmacidal activity occurred in a dose-dependent manner. Furthermore, both activities induced by recombinant IFN-3, could be abrogated with neutralizing monoclonal antibody to IFN-3,. Thus, IFN-3' appears to activate macrophages in both the murine and human systems.
Our results and those previously reported (44, 45) demonstrate that 1 U/ml IFN-3, is sufficient to render murine macrophages tumoricidal. Similarly, low levels of IFN-3, (0.1-1 U/ml) can significantly augment hydrogen peroxide release and induce toxoplasmacidal activity of macrophages (12) . The fact that the MAF assay appears to be 5-10-fold more sensitive than the standard antiviral assay for IFN-3, may be of importance in investigations where macrophage activation is observed with no detection of antiviral activity (46) . Additionally, small molecular weight factors reported to induce macrophage activation (47, 48) may actually be breakdown products of IFN-3,. We have preliminary evidence that fragments of IFN-3, can induce macrophage activation and that the domains for antiviral activity and MAF activity may be distinct (manuscript in preparation).
Macrophage activation is thought to occur by at least a two signal process (49, 50) . The first signal is thought to prime the macrophage to make it receptive to a second triggering signal, as a result of which the macrophage develops full cytotoxic activity. Our data demonstrate that IFN-3, alone is fully able to activate macrophages. However, we have also presented evidence that IFN-3,/MAF activity may be augmented with small amounts of LPS, as has been demonstrated previously (35, 36) . Other, less well-defined substances can also apparently activate or modulate the activation of macrophages, including proteases (51), lipoproteins (52) , tumor cell products (53) , and prostaglandins (54, 55) . Table II represents a summary of preparations of murine origin tested for MAF activity. All of the materials tested that displayed antiviral activity possessed MAF activity. Further, neutralization experiments performed with rabbit antirecombinant murine IFN-3, showed complete abrogation of MAF activity. In addition to recombinant IFN-3,, murine IFN-a, and IFN-13 were also found to have MAF activity. This agrees with Roberts et al. (44) and Pace et al. (15) , who have demonstrated that at least 100-fold more murine IFN-0t//3 than IFN-3, was required to demonstrate the same amount of MAF activity. The MAF (and antiviral) activity of murine IFN-ot and IFN-13 was not neutralized by antimurine IFN-3,. There appears to be a species specificity for expression of MAF activity in the murine assay (Table III) . Recombinant human IFN-a, IFN-/31 and IFN-3", and stimulated leukocyte supernatants obtained from human, bovine, ovine, and guinea pigs did not c~isplay MAF activity towards murine macrophages. One of the purified recombinant human hybrid IFN-a, IFN-ot ADbgl (56), displayed significant levels of murine-directed MAF activity. This hybrid IFN has been reported to be the only human IFN to display antiviral (57) and antitumor properties (58) in murine systems. Interestingly, the MAF (and antiviral) activity of human IFN-a ADbgl was not affected by anti-IFN-3".
In conclusion, murine IFN-3" appears to have potent macrophage activation capabilities. This MAF activity, as well as that induced from a variety of sources, is totally neutralized by affinity-purified antibody to recombinant murine IFN-3'. Collectively, these data strongly argue for the biological and antigenic similarity, if not identity, of these iymphokines. However, it is important to note that total abrogation of MAF activity by anti-IFN-3" does not exclude the possibility that MAF other than IFN exist. Obviously, any antibody molecule has the capacity to bind to either the molecule containing the determinant(s) to which it was raised or to a nonidentical molecule containing either the identical or a similar determinant(s). Thus, the anti-IFN-3" used in these studies might crossreact with a non-IFN-3" protein that had MAF activity. Obtaining a monoclonal antimurine IFN-3" will by useful; however, further studies involving peptide mapping and sequencing will be required to prove identity. 
Summary
Murine peritoneal exudate cells (PEC) treated with murine recombinant interferon-'r (IFN-~) (>99% estimated purity), or concanavalin A-stimulated spleen cell supernatants developed tumoricidal properties (macrophage activation factor [MAF] activity). MAF activity was found to occur with treatments of 10 U/ml IFN-3,, and at levels as low as 1 U/ml IFN-7 if a second signal (5 ng/ml endotoxin) was present in the MAF assay. Endotoxin (lipopolysaccharide [LPS]) alone at these levels failed to induce MAF; induction of MAF was observed at 1,000-fold greater levels. The ability of IFN-3, to stimulate murine PEC was species specific. Various sources of materials that displayed MAF activity, including supernatants from interleukin 2-dependent cloned cytotoxic murine T lymphocyte lines that did not display detectable antiviral activity, were neutralized by antibody raised and affinity purified against recombinant IFN-3,. Thus, IFN-% although never detectable by antiviral assays, appears to be present in many lymphokine preparations and has potent macrophage activation capability.
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